I think we understand the impact of the last ill-advised financing and the almost insurmountable hurdle that caused but I still don't understand why operationally the new facility was not able to generate revenue? Their explanation of higher interest rates and less biotech research never made sense. Was it the wrong market and just a strategic blunder? Also, whatever happened to that Belgium guy?
Market Data 
Markets 
AI
